Tag: Wuhan Zhong Yuan Rui De Biologics
CSL to buy majority stake in a leading Chinese plasma fractionator
Australian biotech firm CSL has agreed to acquire an 80% stake in China’s plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (Ruide) in...
Featured Article
Why manufacturers are embracing AI-powered smart supply chains
Manufacturers are facing an increasingly volatile environment, where rapid changes in demand, supply chain disruptions, and continued cost pressures are transforming the way products are planned, made, and delivered.
